OCT 11, 2017 12:00 PM PDT
Immunotherapy: A revolution in cancer treatment
Presented at the Cancer Research & Oncology 2017 Virtual Event
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: CME | P.A.C.E. CE | Florida CE
1 1 15

Speakers:
  • Distinguished Scientist and Director, Deeley Research Centre, Co-Director, Cancer Immunotherapy Program, BC Cancer Agency
    Biography
      Dr. Nelson is a native of Vancouver BC. He received his B.Sc. from the University of British Columbia in 1987 and Ph.D. from the University of California at Berkeley in 1991. He completed postdoctoral training with Dr. Phil Greenberg and held faculty positions at the Fred Hutchinson Cancer Research Center and University of Washington in Seattle. In 2003, he became the founding Director of the BC Cancer Agency's Deeley Research Centre in Victoria BC. He is a Professor of Medical Genetics at the University of British Columbia and a Professor of Biochemistry/Microbiology at the University of Victoria. Dr. Nelson's lab uses genomic and molecular approaches to study the immune response to cancer, with an emphasis on ovarian cancer. As Co-Director of the BCCA's Immunotherapy Program, he is leading a phase I clinical trials program focused on adoptive T cell therapy for gynecological cancers, leukemia, lymphoma, and other malignancies.

    Abstract:

    Immunotherapy: An unprecedented opportunity

    -Long-lasting/curative treatments
    -Lower side effects
    -Wide applicability
    -Natural mechanism of action
    -Locally produced T cell therapies
        -jobs
        -talent
        -innovation
        -intellectual property
        -cost control


    Show Resources
    Loading Comments...